Table 1.
Characteristics of studies included in the meta-analysis
| Study | Year | Country | Sample size | Tumor type | Cutoff value | Laboratory method | Gender male (+/−)/female (+/−) | Age old (+/−)/young (+/−) | Tumor size big (+/−)/small (+/−) | Differentiation low (+/−)/high and moderate (+/−) | Lymph node metastasis yes (+/−)/no (+/−) | UICC stage I, II (+/−)/III, IV (+/−) | Survival information | HR | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||||
| Lu S | 2017 | People’s Republic of China | 47 | HCC | Median | qRT-PCR | 15/19 | 16/5 | 11/22 | 26/3 | NA | 10/9 | NA | NA | 6 |
| 5/8 | 18/8 | 7/7 | 8/10 | 24/4 | |||||||||||
| Li JF | 2016 | People’s Republic of China | 50 | BC | NA | qRT-PCR | 19/17 | 12/7 | 24/8 | 9/13 | 5/1 | 9/20 | NA | NA | 6 |
| 9/5 | 19/17 | 6/12 | 20/18 | 29/15 | 15/6 | ||||||||||
| Gu P | 2017 | People’s Republic of China | 374 | PC | NA | RNA-Seq | NA | 124/81 | NA | NA | 36/10 | 89/72 | OS | 1.47 (1.01–2.14) (R) | 8 |
| 105/58 | 168/102 | 141/66 | |||||||||||||
| Lu CW | 2017 | People’s Republic of China | 60 | NSCLC | NA | qRT-PCR | 12/19 | 9/18 | 11/23 | NA | 17/12 | 10/32 | OS | 1.37 (1.11–3.07) (C) | 6 |
| 10/19 | 13/20 | 11/15 | 5/26 | 12/6 | |||||||||||
| Wang H | 2017 | People’s Republic of China | 120 | HCC | Median | qRT-PCR | 8/13 | 25/24 | 27/23 | NA | NA | 54/60 | OS | 1.64 (1.09–2.47) (R) | 8 |
| 52/45 | 35/36 | 33/37 | 6/0 | ||||||||||||
| Wang QH | 2017 | People’s Republic of China | 87 | NSCLC | Median | qRT-PCR | 29/21 | 28/24 | 30/12 | NA | NA | 18/22 | OS | 1.92 (1.20–3.71) (C) | 8 |
| 21/17 | 21/14 | 19/26 | 31/16 | ||||||||||||
| Hu YC | 2017 | People’s Republic of China | 122 | CC | NA | qRT-PCR | NA | 36/25 | NA | NA | 18/5 | 27/41 | NA | NA | 6 |
| 31/30 | 49/50 | 40/14 | |||||||||||||
| Zhang HL | 2017 | People’s Republic of China | 25 | Melanoma | Median | qRT-PCR | NA | NA | NA | NA | NA | NA | OS | 2.28 (1.30–5.78) (C) | 6 |
| Zhang Y | 2017 | People’s Republic of China | 43 | EOC | Median | qRT-PCR | NA | 13/14 | 12/13 | NA | 8/2 | 3/10 | OS | 2.01 (1.06–5.53) (C) | 6 |
| 9/7 | 8/10 | 14/19 | 19/11 | ||||||||||||
| Zheng L | 2017 | People’s Republic of China | 104 | GC | Median | qRT-PCR | 33/24 | 28/25 | 39/16 | NA | 34/16 | 19/31 | NA | NA | 7 |
| 26/21 | 31/20 | 20/29 | 25/29 | 40/14 | |||||||||||
| Qu Y | 2018 | People’s Republic of China | 46 | OS | Median | qRT-PCR | 13/9 | NA | 11/7 | 31/21 | 10/1 | 17/19 | OS | 1.37 (1.03–5.94) (C) | 7 |
| 14/10 | 16/12 | 28/18 | 17/18 | 10/0 | |||||||||||
| Wang YY | 2018 | People’s Republic of China | 369 | OS | Median | RNA-Seq | NA | NA | NA | NA | NA | NA | OS | 1.68 (1.01–2.79) (C) | 7 |
| Li X | 2018 | People’s Republic of China | 136 | CRC | Median | qRT-PCR | 38/40 | 38/34 | 37/28 | 35/10 | 46/45 | 14/28 | OS | 1.67 (1.55–2.61) (C) | 8 |
| 30/28 | 30/34 | 31/40 | 33/58 | 22/23 | 54/40 | ||||||||||
| Xia H | 2018 | People’s Republic of China | 52 | NSCLC | Median | qRT-PCR | 14/14 | 17/15 | 11/7 | NA | 11/1 | 16/22 | OS | 1.54 (1.01–2.75) (R) | 8 |
| 14/10 | 11/9 | 17/17 | 17/23 | 12/2 | |||||||||||
| Gu WF | 2018 | People’s Republic of China | 43 | OS | Median | qRT-PCR | 15/11 | 10/13 | 19/9 | NA | NA | 4/10 | OS | 1.81 (1.03–5.18) (C) | 6 |
| 9/8 | 10/13 | 19/9 | NA | NA | 4/10 | OS | 1.81 (1.03–5.18) (C) | 6 | |||||||
Abbreviations: BC, bladder cancer; C, HR was estimated by curve; CC, cervical cancer; CRC, colorectal cancer; EOC, epithelial ovarian cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; NSCLC, non-small-cell lung cancer; OS, osteosarcoma; PC, prostate cancer; R, HR was reported.